Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase--a double-blind, randomized, placebo-controlled study.
BACKGROUND
Hydrating and emollient products are often recommended to patients under isotretinoin therapy to control the most frequent mucocutaneous side effects and to improve adherence to treatment.


OBJECTIVE
To assess, using noninvasive biophysical tests, the clinical and instrumental effectiveness of a hydrating gel-cream compared with placebo as an adjuvant to isotretinoin for treatment of facial skin in patients with inflammatory acne.


METHODS
Prospective, double-blind, randomized study, using MULTI SKIN MC750, on the adjuvant effect of a hydrating gel-cream for acne (active product) vs. a gel-cream without active substances (placebo). Follow-up lasted 3 months.


RESULTS
Sixty-six patients were included. Thirty-four were administered the active product, and 32 placebo. Though the number of lesions fell significantly in both groups, the mean number of papules on day 30 was significantly lower in the active product group. The active product group showed a significant increase in hydration, while the placebo group showed a significant increase in transepidermal water loss (TEWL). Seborrhoea decreased significantly in both groups; there were no differences between them.


CONCLUSIONS
Compared with placebo, the specific gel-cream with active products as an adjuvant to oral isotretinoin improved hydration, prevented TEWL increase, and reduced inflammatory acne lesions after 30 days.
Herane
María Isabel
MI
Hospital Clínico Universidad de Chile, Santiago de Chile, Chile. giderm@yahoo.es
Fuenzalida
Héctor
H
Zegpi
Emilia
E
De Pablo
Carolina
C
Espadas
Maria José
MJ
Trullás
Carles
C
Mirada
Alfons
A
Martin
Guillermo González
GG
D000152:Acne Vulgaris / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D005990:Glycerol / Q000494:pharmacology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000517:prevention & control; D015474:Isotretinoin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D010919:Placebos; D012867:Skin / Q000187:drug effects; D012879:Skin Physiological Phenomena / Q000187:drug effects*; D014870:Water Loss, Insensible / Q000187:drug effects / Q000502:physiology*; D055815:Young Adult
D003879:Dermatologic Agents; D005782:Gels; D010919:Placebos; D015474:Isotretinoin; D005990:Glycerol